Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronpass Tab. in Patients With Stable COPD
NCT06434792Phase 2Recruiting
- Sponsor
- Hanlim Pharm
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Bronpass Tab with Placebo (2 arms). Primary endpoint: Change from baseline in COPD Assessment Test (CAT) total score at 3 months. Started Jun 2023; status: recruiting.
02
Drugs
Bronpass
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06434792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434792.